AbbVie's Skyrizi Gains Pediatric Psoriatic Disease Indication

AbbVie's drug Skyrizi has received a new indication for treating pediatric psoriatic disease. This expansion allows the medication to be used for a younger patient population suffering from the chronic autoimmune condition.